Drug intelligence / Profile preview

MKL002

Development stage: Preclinical
Lead developer: MiHKAL
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

MKL002 is a preclinical-stage small molecule prodrug being developed by MiHKAL GmbH for the treatment of Post-Traumatic Stress Disorder (PTSD). The drug is designed with an undisclosed active ingredient that is enzymatically activated in human blood, utilizing a methodology similar to lisdexamfetamine (Vyvanse) to achieve tunable release kinetics. As a lead candidate in MiHKAL's pipeline of psychedelic and entactogen-based medicines, MKL002 is currently undergoing preclinical testing to validate its safety and efficacy profile. The company's approach focuses on optimizing the pharmacokinetic properties of known or novel psychoactive compounds to improve therapeutic outcomes in psychiatric conditions.

Beyond the preview

Go deeper on MKL002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MKL002.

Explore the full profile